Kenneth Cacciatore's questions to Biohaven (BHVN) leadership • Q1 2021
Question
Kenneth Cacciatore of Cowen and Company asked about the status of FDA interactions for NURTEC ODT's prevention indication and the anticipated impact on sampling and gross-to-net (GTN) upon its approval.
Answer
CEO Vladimir Coric confirmed they are in appropriate discussions with the FDA but could not provide specifics. He and CCO BJ Jones clarified that since the dose and packaging are identical for both acute and preventive use, they do not foresee major changes to their sampling strategy or a significant impact on GTN, noting the efficiency of a single marketing message.